Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type‐2 diabetes patients

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Pharmaceutical Sciences

• Publication date

  2017-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejps.2017.05.033PMID 28522373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years

  2017cited by this paper
• Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism

  2017cited by this paper
• Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers.

  2016cited by this paper
• The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro

  2016cited by this paper
• Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.

  2016cited by this paper
• The total bootstrap median: a robust and efficient estimator of location and scale for small samples

  2015cited by this paper
• Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications

  2015cited by this paper
• Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.

  2015cited by this paper
• Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.

  2014influential reference
• The Pharmacogenetics of Type 2 Diabetes: A Systematic Review

  2014cited by this paper
• Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

  2014cited by this paper
• Population pharmacokinetics of deferiprone in healthy subjects.

  2014cited by this paper
• Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability.

  2014cited by this paper
• Population pharmacokinetics of abacavir in infants, toddlers and children.

  2013cited by this paper
• Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

  2013cited by this paper
• Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

  2013cited by this paper
• Stereoselective Glucuronidation of Carvedilol in Human Liver and Intestinal Microsomes

  2012cited by this paper
• CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects

  2012cited by this paper
• Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome

  2012cited by this paper
• Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs

  2012cited by this paper
• A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study.

  2012cited by this paper
• Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

  2012influential reference
• Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.

  2011cited by this paper
• Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients

  2011cited by this paper
• Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer

  2011cited by this paper
• Recognition of Sulfonylurea Receptor (ABCC8/9) Ligands by the Multidrug Resistance Transporter P-glycoprotein (ABCB1)

  2010cited by this paper
• Potential CYP2C9‐mediated drug–drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide

  2010cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients

  2009cited by this paper
• Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.

  2008cited by this paper
• Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R

  2008influential reference
• Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method

  2007cited by this paper
• Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)

  2007cited by this paper
• Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.

  2007cited by this paper
• Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI

  2007cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound

  2005influential reference
• A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism.

  2005cited by this paper
• PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM

  2005influential reference
• New positron emission tomography tracer [11C]carvedilol reveals P‐glycoprotein modulation kinetics

  2005cited by this paper
• Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance

  2004cited by this paper
• Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.

  2004cited by this paper
• ANALYSIS OF POPULATION PHARMACOKINETIC DATA USING NONMEM AND WinBUGS

  2004cited by this paper
• CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects

  2004cited by this paper
• Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

  2004cited by this paper
• Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker

  2004cited by this paper
• Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.

  2003cited by this paper
• Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

  2003cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

  2002influential reference
• Assessment of Actual Significance Levels for Covariate Effects in NONMEM

  2001influential reference
• Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check

  2001cited by this paper
• Diabetes, Hypertension, and Cardiovascular Disease: An Update

  2001cited by this paper
• Diabetes, hypertension, and cardiovascular disease.

  2001cited by this paper
• Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

  2000cited by this paper
• Steady‐State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure

  2000cited by this paper
• Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus

  2000cited by this paper
• P-glycoprotein inhibition by glibenclamide and related compounds

  1999cited by this paper
• A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

  1999cited by this paper
• The anglo-scandinavian cardiac outcomes trial (ASCOT)

  1998cited by this paper
• IN VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME P 450 ENZYMES INVOLVED IN THE METABOLISM OF R ( 1 )-AND S ( 2 )-CARVEDILOL

  1997cited by this paper
• Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

  1997cited by this paper
• In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.

  1997cited by this paper
• Differential effect of chronic treatment with two beta‐blocking agents on insulin sensitivity: the carvedilol‐metoprolol study

  1996cited by this paper
• Stereoselective disposition of carvedilol is determined by CYP2D6

  1995cited by this paper
• Utility of a One‐Point (3‐Hour Postdose) Plasma Metabolic Ratio as a Phenotyping Test Using Metoprolol in Two East Asian Populations

  1992cited by this paper
• Metabolism of carvedilol in man

  1991cited by this paper
• A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam

  1991cited by this paper
• High-performance liquid chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its O-desmethyl metabolite in human plasma after chiral derivatization.

  1989cited by this paper
• Diabetes Mellitus and Hypertension State of the Art Lecture

  1988cited by this paper
• Pharmacokinetics and Disposition of Carvedilol in Humans

  1987cited by this paper
• Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.

  1985cited by this paper
• Disappearance Rate of Tolbutamide in Normal Subjects and in Diabetes Mellitus, Liver Cirrhosis, and Renal Disease

  1963cited by this paper

• Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers

  2024cites this paper
• Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population‐based analysis

  2024cites this paper
• Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis

  2023cites this paper
• Advances and challenges in the pharmacokinetics and bioanalysis of chiral drugs.

  2022cites this paper
• Review Carbazoles: Role and Functions in Fighting Diabetes Fedora Grande 1

  2022cites this paper
• Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS/MS method.

  2022cites this paper
• Niosome-carvedilol protects DNA damage of supraphysiologic concentrations of insulin using comet assay: An in vitro study

  2021cites this paper
• Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties

  2021cites this paper
• Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports

  2020cites this paper
• Population Insulin Sensitivity from Sparsely Sampled Oral Glucose Tolerance Tests.

  2020cites this paper
• INFLUENCE OF FLUVOXAMINE ON CARVEDILOL’S PHARMACOKINETICS IN RATS

  2019cites this paper
• Factors influencing hepatic metabolism of antihypertensive drugs: impact on clinical response

  2019cites this paper
• Simultaneous quantification of Schisandrin B enantiomers in rat plasma by chiral LC–MS/MS: Application in a stereoselective pharmacokinetic study

  2018cites this paper
• Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle.

  2018cites this paper